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Background & Aims: Helicobacter pylori is believed to
predispose to gastric cancer by inducing gastric atro-
phy and hypochlorhydria. First-degree relatives of pa-
tients with gastric cancer have an increased risk of
developing gastric cancer. The aim of this study was to
determine the prevalence of atrophy and hypochlorhy-
dria and their association with H. pylori infection in
first-degree relatives of patients with gastric cancer.
Methods: H. pylori status, gastric secretory function,
and gastric histology were studied in 100 first-degree
relatives of patients with noncardia gastric cancer and
compared with those of controls with no family history
of this cancer. Results: Compared with healthy con-
trols, relatives of patients with gastric cancer had a
higher prevalence of hypochlorhydria (27% vs. 3%) but
a similar prevalence of H. pylori infection (63% vs.
64%). Relatives of cancer patients also had a higher
prevalence of atrophy (34%) than patients with nonul-
cer dyspepsia (5%) matched for H. pylori prevalence.
Among the relatives of cancer patients, the prevalence
of atrophy and hypochlorhydria was increased only in
those with evidence of H. pylori infection, was greater
in relatives of patients with familial cancer than in
relatives of sporadic cancer index patients, and in-
creased with age. Eradication of H. pylori infection
produced resolution of the gastric inflammation in
each subject and resolution of hypochlorhydria and
atrophy in 50% of the subjects. Conclusions: Relatives
of patients with gastric cancer have an increased
prevalence of precancerous gastric abnormalities, but
this increase is confined to those with H. pylori infec-
tion. Consequently, prophylactic eradication of the
infection should be offered to such subjects.
Gastric cancer remains the second most commoncause of cancer deaths on a world-wide basis. There
is a well-recognized familial predisposition to the cancer,
and the risk of developing it is greater in relatives of
patients with familial cases of the cancer, in which more
than 1 relative has been affected, than in relatives of
sporadic index patients.1–5
Helicobacter pylori infection is present in 50% of the
world’s population, and infected subjects have an in-
creased risk of developing cancer of the mid and distal
stomach.6–9 The risk of developing gastric cancer is
related to the histological and functional changes the
infection induces in the stomach.10–14 In most H. pylori–
infected subjects, the inflammation is largely confined to
the antral mucosa and is accompanied by little if any
atrophy. In subjects with this pattern of gastritis, gastric
acid secretion is normal or increased. Such subjects have
an increased risk of developing duodenal ulceration but
little if any increased risk of gastric cancer. In other
subjects, the inflammation involves the body region of
the stomach to a degree similar to or greater than that
seen in the antral region. This pangastritis and body-
predominant pattern of gastritis is usually accompanied
by various degrees of atrophy and impairment of acid-
secretory function. This latter subgroup of subjects with
H. pylori–induced atrophic gastritis and hypochlorhydria
has a markedly increased risk of noncardia gastric cancer.
Gastric mucosal atrophy and hypochlorhydria are long-
recognized cancer-associated abnormalities.15–21
Little is known about the role of H. pylori infection as a
risk factor for gastric cancer in subjects with a family
history of this cancer. If the infection is intimately
involved in the development of gastric cancer in these
subjects, they provide an easily identified subgroup of
infected subjects for prophylactic H. pylori eradication
therapy.
We examined the prevalence of atrophy and hypochlor-
hydria in first-degree relatives of patients with noncardia
gastric cancer and the association between these precancer-
ous abnormalities and H. pylori infection. We also
Abbreviations used in this paper: CI, confidence interval; NUD,
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examined the reversibility of these abnormalities by
eradicating the infection.
Subjects and Methods
The overall design of the study involved examining H.
pylori status, gastric secretory function, and gastric histology in
first-degree relatives of patients with noncardia gastric cancer.
Healthy volunteers were used as controls for the gastric
secretory studies. In view of the ethical difficulties of perform-
ing endoscopy in a large number of healthy volunteers, patients
with nonulcer dyspepsia (NUD) were used as controls for the
histological study. The study was approved by the Western
Infirmary Ethics Committee.
Recruitment of First-Degree Relatives
and Controls
Case records of all patients with gastric cancer diag-
nosed in our hospital between 1991 and 1995 were examined,
and all patients with documented, histopathologically proven
noncardia gastric adenocarcinoma were identified. Surviving
siblings or children of these index patients were invited to
participate in the study. Relatives were excluded if either were
younger than 18 or older than 75 years or had other serious
medical problems.
One hundred first-degree relatives of 40 gastric cancer index
patients were recruited in this way (98 white, 2 Chinese). The
maximum possible number of living and eligible relatives of
the 40 index cases was 142. One hundred eighteen were
contacted, but 13 declined to take part and 5 had serious
medical problems.
The mean age of the 40 gastric cancer patients at the time of
diagnosis was 67 years (range, 37–88 years). The histology of
the 40 cancers showed intestinal type in 10, diffuse type in 17,
and elements of both types in 8. In the other 5, details of the
exact subtype were not available. The mean age of the 100
cancer relatives was 43.7 years (range, 20–67 years); 24 were
siblings and 76 were children of the index patients. Of the 100
cancer relatives, 61 had only 1 relative known to have gastric
cancer and 39 had more than 1 relative with the condition.
One hundred healthy subjects with no family history of
gastric cancer were recruited as controls for the gastric acid
secretion studies. Fifty of these were spouses of the cancer
relatives, and the other 50 were recruited from the local
population so that the control group was similar to the relatives
of cancer patients with respect to age, sex, body weight, and
social class. The healthy controls were selected without knowl-
edge of their H. pylori status.
The control group for the histological study was obtained
from patients who were concurrently undergoing upper gastro-
intestinal endoscopy for investigation of dyspepsia and had no
evidence of esophagitis, ulcer disease, or cancer. Sixty of these
patients with NUD and no family history of gastric cancer were
selected to be similar to the first-degree relatives of cancer
patients in age, sex, body weight, and social class. They were
also selected to match the first-degree relatives for prevalence of
H. pylori infection because of the recognized association
between H. pylori infection and atrophic gastritis. These
controls were selected without knowledge of histological
status; H. pylori status was determined based on their 14C-urea
breath and CLOtests.
Assessment of Cancer Relatives, Healthy
Controls, and NUD Controls
All subjects underwent a 14C-urea breath test as
described previously.22 Cancer relatives and healthy controls
underwent acid-secretory studies. Cancer relatives and NUD
controls underwent upper gastrointestinal endoscopy to obtain
gastric biopsy specimens and had blood taken for determina-
tion of H. pylori immunoglobulin (Ig) G serology as previously
described.
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During endoscopic examination, biopsy specimens
were obtained from the antral region within 2 cm of the pyloric
ring and from the body region of the stomach between 50 and
55 cm along the greater curvature. A biopsy specimen from
each site was used for the rapid urease slide test (CLOtest; Delta
West Pty. Ltd., Bentley, Australia), 1 biopsy specimen was used
for culture, and 3 biopsy specimens from each site were placed
in 10% formalin and submitted for histological examination.
Assessment of Gastric Histology
The antral and body biopsy specimens were embedded
in paraffin, and 4-µm sections were obtained. Sections at 3
levels were stained with H&E and assessed for the parameters
discussed below. One section was stained using cresyl fast violet
for assessment of H. pylori colonization. In equivocal cases,
immunohistochemistry was used to confirm the presence or
absence of H. pylori organisms. The biopsy specimens were
scored blindly without knowledge of diagnosis or acid output.
All histological analyses were performed by 1 observer (K.O.).
Five morphological parameters were assessed using the Sydney
system24–27 and graded from 0 to 3 (0, none; 1, mild; 2,
moderate; 3, severe). The 5 parameters were (1) inflammation,
which scored the chronic inflammatory infiltrate in the lamina
propria; (2) activity, which scored the acute inflammatory
infiltrate; (3) atrophy, which was scored on the basis of the
presence and proportion of glandular loss24,25; (4) intestinal
metaplasia, scored as absent or occupying less than one third,
more than one third, or more than two thirds of the mucosa
present; and (5) density of H. pylori colonization. Inflammation
and activity scores (1 and 2) were added together for a
combined (acute and chronic) inflammatory score with a
maximum possible score of 6.
Assessment of Gastric Acid Secretion
Peak acid output (PAOPG) was assessed in response to
pentagastrin (Peptavlon; ICI, Cheshire, England) infused intra-
venously at a rate of 0.6 µg · kg21 · h21 for 1 hour as described
previously.14
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Assessment of H. pylori Status in Cancer
Relatives and Healthy Controls
In relatives of cancer patients, H. pylori status was
considered positive if results of 2 or more of the 5 tests were
positive. In the healthy controls, H. pylori status was based on
results of the 14C-breath test, which we have shown to have a
sensitivity of 98% and specificity of 100% using histology plus
the urease slide test as a gold standard.22
Eradication of H. pylori
After assessment, all H. pylori–positive cancer relatives
received H. pylori eradication therapy in the form of a 1-week
course of omeprazole, 20 mg twice daily; amoxicillin, 500 mg
3 times daily; and clarithromycin, 500 mg 3 times daily. For
infected cancer relatives with hypochlorhydria, metronidazole,
400 mg 3 times daily, instead of omeprazole was used. Six
weeks after this treatment, a 14C-urea breath test was per-
formed to assess success of eradication. In those in whom the
initial eradication regimen failed, a 2-week course of clarithro-
mycin, 500 mg 3 times daily; amoxicillin, 500 mg 3 times
daily; and either tripotassium dicitratobismuthate (Denol),
120 mg 3 times daily, or metronidazole, 400 mg 3 times daily,
was given. Patients were reassessed as described above. All
cancer relatives were invited back 11 months after eradication
assessment to undergo posteradication studies.
Statistical Analysis
Comparison of medians in the different groups was
made using the Kruskal–Wallis test. Pairwise comparisons
were made using a Mann–Whitney test and confidence inter-
val. When multiple comparisons were made after a significant
Kruskal–Wallis test result, confidence intervals and P values
were corrected using the Bonferroni method. Prevalence rates
were compared using a x2 test. For those with a 1-year
follow-up, the change in scores was analyzed using a Wilcoxon
signed-rank test and confidence interval (CI), and the change in
prevalence rate was assessed using the McNemar test. Risk
factors for hypochlorhydria and atrophy were determined using
stepwise logistic regression. The computing packages SPSS and
Minitab were used for data analysis. All tests were 2-sided.
Results
H. pylori Infection
The prevalence (95% CI) of H. pylori infection was
63% (53%–72%) in cancer relatives and 64% (54%–
73%) in healthy controls. In all 63 H. pylori–positive
relatives of cancer patients, infection was eradicated
successfully after 1 or 2 courses (9 subjects) of treatment.
Forty-three relatives of cancer patients agreed to repeat all
tests 1 year after eradication of the infection; of these, 40
remained H. pylori–negative at that time.
Endoscopic Abnormalities
Of the 63 H. pylori–positive relatives of cancer
patients, 8 (13%) were found to have peptic ulcers (5
duodenal, 2 prepyloric, and 1 both). Only 3 of the 8
subjects with ulcers had ever experienced any dyspeptic
symptoms, and none were receiving antiulcer medication.
In addition to the 8 subjects with ulcers, 6 other subjects
had small hiatus hernias and 2 had grade 1 esophagitis.
None of the 37 H. pylori–negative cancer relatives had any
significant endoscopic abnormalities apart from 4 sub-
jects who had small hiatus hernias.
Acid-Secretory Status of Cancer Relatives
Versus Healthy Controls
The individual acid outputs and H. pylori status
for cancer relatives and healthy controls are shown in
Figure 1. The median values of acid output in the 4
groups were significantly different (P # 0.001). Pairwise
comparison of the H. pylori–positive cancer relatives with
H. pylori–positive controls showed that the median value
for the former was significantly lower than that for the
latter (P # 0.001; 95% CI for difference in medians,
7–14 mmol/h). There was no evidence of a difference
between H. pylori–negative cancer relatives and H. pylori–
negative controls (P 5 0.39; 95% CI, 22 to 6 mmol/h).
The prevalence of hypochlorhydria in cancer relatives
(i.e., PAOPG , 15 mmol/h) was 27%, compared with 3%
in the healthy controls (95% CI for difference in preva-
lence in these 2 groups, 15%–33%; P , 0.001). This
high prevalence of hypochlorhydria in cancer relatives
was attributable to its high prevalence in H. pylori–
positive cancer relatives (40%) compared with that in
Figure 1. Individual PAO values in H. pylori (HP)-positive and -negative
first-degree relatives of gastric cancer patients and controls. Median
values are shown by horizontal bars. The median acid output of
HP-positive relatives of cancer patients is lower than that of HP-
positive controls (P , 0.001). The median acid output of HP-negative
relatives of cancer patients is not different from that of HP-negative
controls (P 5 0.39).
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H. pylori–negative cancer relatives (5%) (95% CI for
difference in prevalence rates, 20%–48%; P # 0.001).
Few H. pylori–positive controls (5%) and no H. pylori–
negative controls had hypochlorhydria.
In H. pylori–positive cancer relatives, the median
PAOPG in the 8 subjects with ulcers was 39.1 mmol/h,
which was significantly higher than the median (18.1
mmol/h) for those without ulcers (P , 0.001; 95% CI for
difference in medians in ulcer and nonulcer groups,
12–30 mmol/h). The individual acid output values are
shown in Figure 1.
A logistic regression analysis was performed in cancer
relatives to determine risk factors for hypochlorhydria.
Age, H. pylori status, duodenal ulcer, relationship to
cancer patient (offspring or sibling), gender, whether the
relative with cancer had familial cancer or was a sporadic
index case, and position among siblings within the family
were considered potential risk factors. In a stepwise
analysis, only age (P , 0.001), H. pylori status (P 5
0.01), and whether the cancer was familial or a sporadic
index case (P 5 0.02) were significant predictors of
hypochlorhydria.
One year after eradication of H. pylori, the median
PAOPG in the 40 of 63 H. pylori–positive cancer relatives
who were studied increased from 15.3 mmol/h (range,
0–46.1 mmol/h) to 21.6 mmol/h (range, 0.6–50 mmol/h).
The 95% CI for the median increase was 1.7–5.5mmol/h
(P 5 0.004). The increase in acid output was caused by
the increase in the 20 who were hypochlorhydric at
presentation; their median acid output increased from 9.8
mmol/h (range, 0–14.6 mmol/h) to 16.1 mmol/h (range,
0.6–24 mmol/h) 1 year after eradication. The 95% CI for
the median increase was 3.7–9.0 mmol/h (P , 0.001)
(Figure 2). Of the 20 subjects who were hypochlorhydric
before treatment, 50% had restoration of normal levels of
acid secretion after eradication of the infection.
Gastric Histology in Cancer Relatives
Compared With NUD Controls
Combined inflammatory score. The median an-
tral combined inflammatory score in the 63 H. pylori–
positive cancer relatives was 5 (range, 0–6), which was
similar to that in the H. pylori–positive NUD controls
(median, 4.5; range, 0–6; P 5 0.78). Both were signifi-
cantly higher than the median in H. pylori–negative
cancer relatives (median, 0; range, 0–2; both P , 0.001)
or H. pylori–negative NUD controls (median, 1; range,
0–3; both P , 0.001). The median body inflammatory
score in the 63 H. pylori–positive cancer relatives was 3
(range, 0–6), which was higher than the median for the
H. pylori–positive NUD controls (median, 2; range, 0–5;
P 5 0.03). Scores in both H. pylori–positive groups were
significantly higher than the median for the H. pylori–
negative cancer relatives (median, 1; range, 0–1; both
P , 0.001) or H. pylori–negative NUD controls (median,
1; range, 0–2; both P , 0.001).
One year after eradication of H. pylori infection, in the
40 cancer relatives who remained infection free, both the
median antral and body inflammatory scores decreased
from 4 to 1. The 95% CIs for the median decrease in
antral and body inflammatory scores were 2.5–3.0 (P ,
0.001) and 2.0–3.0, respectively (P , 0.001).
Atrophy. The prevalence of atrophy of antrum
and/or body mucosa in the 100 cancer relatives was 34%,
which was significantly higher (P , 0.001) than the 5%
prevalence in NUD patients. The increased prevalence of
atrophy in the cancer relatives was caused by a high
prevalence of atrophy (52%) in the H. pylori–positive
cancer relatives, compared with a prevalence of 3% in H.
pylori–negative cancer relatives, 5% in H. pylori–negative
NUDs, and 5% in H. pylori–positive NUDs.
The severity and distribution of atrophy within the
stomach are shown in Table 1. Of the 33 H. pylori–
positive cancer relatives with atrophy, it was of grade 1
severity in 24, grade 2 severity in 8, and grade 3 severity
in 2. The atrophy affected only the antral region in 9,
only the body region in 14, and both the antral and body
regions in 10 subjects.
Logistic regression analysis was performed to identify
risk factors for atrophy in the cancer relatives as before. In
addition to H. pylori status (P 5 0.002), only age (P ,
0.001) and whether the relative’s cancer was a familial or
sporadic index case (P 5 0.02) predicted atrophy.
One year after eradication of H. pylori infection, the
prevalence of atrophy decreased from 63% to 38% (P ,
0.002). This was mainly caused by resolution in those
Figure 2. Effect of eradication of H. pylori infection on PAO in
response to pentagastrin in H. pylori–positive cancer relatives who (A)
were and (B) were not hypochlorhydric (PAO , 15 mmol/h) on initial
presentation. Acid secretion was reassessed 1 year after eradication
of H. pylori. Note that the scale of the y axis is different in the 2
figures. Median values are shown by horizontal bars.
January 2000 ROLE OF H. PYLORI IN FAMILIAL GASTRIC CANCER 25
with mild degrees of atrophy before treatment (Table 2).
Of the 25 subjects with atrophy at presentation, resolu-
tion of normal mucosal appearance was achieved in 12
after eradication of the infection.
Intestinal metaplasia. The prevalence of intestinal
metaplasia in the antrum and/or body mucosa was 19%
in cancer relatives and 12% in NUD controls (P 5 0.22).
In both groups, the prevalence of intestinal metaplasia
was higher in those with evidence of H. pylori infection
(Table 1).
One year after eradication of H. pylori infection, there
was no overall change (P 5 0.2) in the degree of intestinal
metaplasia in the 40 cancer relatives who were studied.
Association Between Gastric Secretory
Function and Gastric Histology in
H. pylori–Positive Cancer Relatives
In H. pylori–positive cancer relatives, there was an
association between the presence of hypochlorhydria and
atrophy (Table 3). Atrophy was present in 84% of the
hypochlorhydric subjects and only 32% of those without
hypochlorhydria (P # 0.001). The hypochlorhydric
subjects also had evidence of more severe body gastritis
than the normochlorhydric subjects (median scores of 4
and 2, respectively; P # 0.001), and a higher prevalence
of pangastritis or body-predominant distribution of
gastritis (44% vs. 5%; P # 0.001). In addition, a higher
proportion of the hypochlorhydric subjects had body-
predominant H. pylori colonization (36% vs. 13%; P #
0.04).
Discussion
This study indicates that relatives of patients with
noncardia gastric cancer have an increased prevalence of
gastric atrophy and hypochlorhydria. The prevalence of
hypochlorhydria was 27% in cancer relatives compared
with 3% in controls, and that of atrophy was 34%
compared with 5% in controls. Our findings of increased
prevalence of atrophic gastritis and hypochlorhydria in
relatives of gastric cancer patients are consistent with
findings of previous studies28–31 and supports a role for
these abnormalities in the sequence of events leading to
noncardia gastric cancer.
In the present study, we were able to extend previous
work by demonstrating that the precancerous abnormali-
ties prevalent in relatives of patients with cancer were
confined almost entirely to H. pylori–infected subjects
(Figure 3). The prevalence of atrophy in the cancer
relatives with H. pylori infection was 52%, compared
with 3% in those without H. pylori infection. Likewise,
the prevalence of hypochlorhydria was 40% in the H.
pylori–positive cancer relatives and 5% (2 subjects) in
those not infected. The association between H. pylori
infection and these precancerous abnormalities may be
even stronger because of the likelihood that the 2 H.
pylori–negative subjects with gastric abnormalities had
been infected at some time. One of these 2 patients had
atrophy and hypochlorhydria and came from a family of
10 siblings. All of the 4 surviving siblings had evidence
Table 1. Prevalence and Severity of Atrophy and Intestinal
Metaplasia of Antrum and Body of Stomach in H.
pylori–Positive and –Negative Relatives of Patients
With Gastric Cancer and Controls With NUD
Cancer patients’
relatives NUD controls
H. pylori 1
(n 5 63)
H. pylori 2
(n 5 37)
H. pylori 1
(n 5 40)
H. pylori 2
(n 5 20)
Atrophy
Antrum alone 9 (14%) 0 (0%) 1 (2.5%) 0 (0%)
Grade 1-2-3a 6-3-0 1-0-0
Body alone 14 (22%) 0 (0%) 1 (2.5%) 1 (5%)
Grade 1-2-3a 11-2-1 1-0-0 0-1-0
Both (antrum, body) 10 (16%) 1 (3%) 0 (0%) 0 (0%)
Grade (1, 1)-(1, 2)-
(2, 1)-(2, 2)b 7-1-1-1 0-0-0-1
Either (any) 33 (52%) 1 (3%) 2 (5%) 1 (5%)
Intestinal metaplasia
Antrum alone 11 (17%) 1 (3%) 6 (15%) 0 (0%)
Grade 1-2-3a 6-5-0 0-1-0 6-0-0
Body alone 2 (3%) 0 (0%) 0 (0%) 1 (5%)
Grade 1-2-3a 1-1-0 1-0-0
Both (antrum, body) 4 (6%) 1 (3%) 0 (0%) 0 (0%)
Grade (1, 1)-(1, 2)-
(2, 2)-(3, 3)b 1-1-2-0 0-0-0-1
Either (any) 17 (27%) 2 (6%) 6 (15%) 1 (5%)
aNumber of subjects in the 3 different categories of severity of atrophy
(eg, 6-3-0 indicates 6 subjects with grade 1, 3 with grade 2, and 0 with
grade 3).
bNumber of subjects with the different combinations of severity of
atrophy of both antrum and body (eg, 7-1-1-1 indicates 7 subjects with
antrum grade 1 and body grade 1, 1 subject with antrum grade 1 and
body grade 2, 1 subject with antrum grade 2 and body grade 1, and 1
subject with antrum grade 2 and body grade 2).
Table 2. Atrophy Score at First Examination and After 1 Year
of Follow-up in 40 Cases in Which Infection
Was Eradicated
Atrophy (antrum,
body) score
at first examination
Atrophy (antrum, body) score at 1 year
0, 0 0, 1 0, 2 1, 0 1, 1 1, 3 2, 0 2, 2 Total
0, 0 14 1 0 0 0 0 0 0 15
0, 1 5 1 1 0 0 0 1 0 8
0, 2 1 0 0 0 0 1 0 0 2
0, 3 0 0 1 0 0 0 0 0 1
1, 0 3 1 0 0 1 0 0 0 5
1, 1 2 0 0 1 2 0 0 0 5
1, 2 1 0 0 0 0 0 0 0 1
2, 0 0 0 0 1 0 0 1 0 2
2, 2 0 0 0 0 0 0 0 1 1
Total 26 3 2 2 3 1 2 1 40
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of H. pylori infection, and 2 siblings who died of gastric
cancer also had documented evidence of H. pylori infec-
tion. Therefore, it is likely that this subject had been
infected and that the infection had disappeared after its
induction of atrophy and achlorhydria. The only other H.
pylori–negative patient with hypochlorhydria (PAOPG,
11.8) is a 67-year-old missionary who had worked in
remote regions of Africa for much of his life. He had
taken many antibiotics, including metronidazole, during
his stay in Africa. It is likely that this subject also had the
infection, and it was eradicated by antibiotic treatment.
When other evidence of probable previous infection is
taken into account, it appears that atrophy and hypochlor-
hydria might be entirely confined to cancer relatives with
current or previous H. pylori infection.
Among the H. pylori–infected cancer relatives, there
was a positive close correlation of the presence of
hypochlorhydria and atrophy. In addition, those with
hypochlorhydria had more severe inflammation of the
body region of their stomach. The hypochlorhydric
subjects also had a more body-predominant distribution
of H. pylori colonization and a much higher prevalence of
a body-predominant or pangastritis distribution of the
inflammation. We have previously reported that a sub-
group of H. pylori–infected subjects develop this func-
tional and histological response to the infection and
postulated that those subjects are the ones most likely to
progress to gastric cancer.14
The histological diagnosis of atrophy is generally
recognized to be difficult, particularly when the process is
in its early stage. Gastric acid secretion is a much more
quantifiable entity, and reduction in gastric acid output
correlates with both atrophy and the H. pylori–associated
pattern of gastritis progressing to atrophy. Combined
assessment of gastric function and gastric histology is
thus very useful in obtaining a reliable assessment of the
overall state of the gastric mucosa.
The mean age of gastric cancer relatives at examination
was 23 years lower than the age of the cancer index cases
at diagnosis. Consequently, examination of the relatives
provides insight into changes in the gastric mucosa that
occurred many years before the development of the cancer
itself. Our findings that atrophy and hypochlorhydria are
more prevalent in cancer relatives support a role for these
abnormalities in the sequence of events leading to the
cancer. In addition, that these abnormalities are almost
entirely confined to H. pylori–positive subjects supports
the role of the infection in their pathogenesis. Together,
these observations provide strong evidence that the
infection plays an important role in the pathogenesis of
gastric cancer.
The increased prevalence of atrophy and hypochlorhy-
dria in the cancer relatives was not explained by any
increased prevalence of H. pylori infection. Rather, it
appeared to be the result of an increased propensity to
develop atrophy and hypochlorhydria in response to
infection. Several mechanisms could explain this. It could
Figure 3. Prevalence of gastric atrophy (j) and hypochlorhydria (h) in
first-degree relatives of gastric cancer patients and controls, both
grouped according to H. pylori (HP) status. Numbers of subjects are
indicated in parentheses at the foot of each column. The controls for
prevalence of hypochlorhydria consisted of 50 spouses of the cancer
relatives and 50 volunteers matched for age, sex, body weight, and
social class. The controls for prevalence of atrophy consisted of
patients with NUD matched for age, sex, social class, and prevalence
of HP infection.
Table 3. Comparison of Gastric Mucosa Histology in H. pylori–Positive Cancer Relatives With and Without Hypochlorhydria
(PAO ,15 mmol/h)
Normochlorhydric
(n 5 38)
Hypochlorhydric
(n 5 25)
95% CI for difference
between groups P
Prevalence of atrophy 12 (32%) 21 (84%) 32%–73% ,0.001
Severity of body gastritisa 2 (0–6)c 4 (1–6)c 0.9–2.5 ,0.001
Severity of antral gastritisa 5 (2–6)c 4 (0–6)c 20.0–1.0 0.24
Prevalence of pangastritis plus body-predominant gastritisb 2 (5%) 11 (44%) 18%–59% ,0.001
Prevalence of H. pylori colonization density greater in body than antrum 5 (13%) 9 (36%) 12%–45% ,0.04
aCombined inflammatory score (i.e., acute 1 chronic inflammatory cell infiltrate).
bSubjects in whom the combined inflammatory score of the body region was equal to or greater than that of the antral region.
cMedian (range).
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be caused by particularly virulent strains of the infection
that could be transmitted between family members. The
best bacterial marker of increased pathogenic virulence is
the presence of the CagA pathogenic island.32 However,
more than 50% of our infected general population and
NUD patients have this strain, and even an increased
prevalence of 100% CagA positivity in the gastric cancer
relatives would be insufficient to account for the degree of
increased prevalence of precancerous abnormalities. Other
bacterial virulence factors may be important.33
Host genetic factors may be important in determining
the response to H. pylori infection; this possibility is
supported by our finding that the prevalence of atrophy
and hypochlorhydria was greater in relatives of patients
with familial cancer than in relatives of sporadic index
patients. Azuma et al.34 recently reported that absence of
the DQA1*O102 allele may confer susceptibility to
atrophy and gastric adenocarcinoma in H. pylori–infected
subjects.
It has been proposed that the host’s premorbid acid-
secretory status influences the outcome of the infection.35
High acid secretion confines the gastritis to the antrum,
whereas low acid secretion allows development of pangas-
tritis.36,37 We were able to test this hypothesis by
comparing the acid-secretory status of the uninfected
gastric cancer relatives with that of uninfected controls.
Acid output in these 2 groups was the same, thus
providing no evidence that premorbid familial acid
hyposecretion explains the increased tendency to have an
abnormal response to H. pylori infection in relatives of
patients with gastric cancer.
Environmental factors in early life, such as deficiency
of dietary antioxidants, might influence responses to H.
pylori infection.38 However, we found that the prevalence
of precancerous abnormalities was similar in offspring
and siblings, although siblings had childhoods more
similar to those of the index cancer patients.
It is probably naive to presume that a single entity will
explain why some people develop hypochlorhydria and
atrophy in response to H. pylori infection. It is more likely
that the response is caused by the combined effects of
bacterial pathogenicity, dietary antioxidant deficiency,
and the nature of the host’s genetically determined
immune response to the organism. Our current family
studies certainly point toward a significant role for host
genetics.
Logistic regression analysis showed that the age of the
subjects was a strong predictor of the likelihood of
precancerous abnormalities in H. pylori–positive cancer
relatives. It is unclear to what extent the association with
age is attributable to progressive development of the
abnormalities as the subjects grow older or a cohort effect
related to environmental or dietary conditions in previous
years.
One of the unexpected findings in our study was the
high prevalence (13%) of previously unrecognized peptic
ulcers in H. pylori–positive cancer relatives. Five of the 8
patients with ulcers were completely asymptomatic, and
the others reported a history of only mild dyspepsia for
which no medical advice had been sought. Two previous
European studies of the H. pylori–positive general popula-
tion have found a high prevalence of ulcers at endoscopy
(14% and 21%); most of these ulcers were asymptom-
atic.39,40
In the present study, we also investigated the effect of
eradication of H. pylori infection on the histological and
functional abnormalities involved in the carcinogenic
cascade. Eradication of the infection resulted in complete
resolution of inflammation and partial resolution of both
hypochlorhydria and atrophy. One year after eradication
of the infection, a normal level of acid secretion was
restored in 50% of those who had been hypochlorhydric,
and there was no evidence of atrophy in 48% of those
with atrophy at presentation. The resolution of atrophy
was confined to those with grade 1 severity of atrophy at
presentation.
In summary, we found that relatives of patients with
noncardia gastric cancer have an increased prevalence of
hypochlorhydria and atrophy and that these precancerous
abnormalities are almost entirely confined to subjects
with H. pylori infection. These findings indicate a critical
role of H. pylori infection in the process of events leading
to noncardia gastric cancer in subjects with a family
history of this tumor.
Our findings raise an important clinical and public
health issue. Should subjects with a family history of
noncardia gastric cancer be routinely screened for H.
pylori infection and treated if it is present? The answer to
this question depends on the effectiveness of such treat-
ment in prevention of cancer development. Treatment of
H. pylori infection resolves the inflammatory gastritis in
all cases and restores normal structure and secretory
function to approximately 50% of those with hypochlor-
hydria and atrophy before treatment. This is likely to at
least reduce the risk of progression to cancer. Because
resolution of atrophy was seen only in those with grade 1
severity, eradication of the infection at an early stage in
the disease process is likely to be important.
The appropriateness of prophylactic treatment for any
condition also depends on the acceptability of the
treatment and the gravity of the condition one is trying
to prevent. H. pylori eradication therapy is inexpensive
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and safe, whereas gastric cancer is usually a rapidly fatal
disorder.
Taking our findings and the above considerations
together, we believe subjects with a family history of
noncardia gastric cancer should be offered noninvasive H.
pylori screening and eradication therapy if test results are
positive. This policy will be particularly important in
subjects with a strong family history of noncardia gastric
cancer.
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George Blumer (1872–1962) was born at Darlington, England, and at age 17
emigrated with his family to California where he matriculated at the Cooper
Medical College in San Francisco (the forerunner of Stanford’s medical
school). Following a year of internship at the San Francisco County Hospital,
he traveled to Baltimore where he served as house office in surgery under
Halsted, then in medicine under Osler and as assistant in pathology under
Welch. In 1896 he was appointed director of the Bender Hygienic Laboratory
and professor of pathology at the Albany Medical College. From 1906 to
1920 he served as professor of medicine at Yale, the last 10 years as dean. A
prolific writer, he authored a 3-volume text on bedside diagnosis. In 1909 he
described the palpable shelf, ‘‘a neglected rectal sign of value in the diagnosis
and prognosis of obscure malignant and inflammatory disease within the
abdomen.’’ Gifted by wit and charm, he was esteemed as a consummate
clinician.
—Contributed by WILLIAM S. HAUBRICH, M.D.
Scripps Clinic and Research Foundation, La Jolla, California
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